Saniona AB (SANION) - Total Liabilities
Based on the latest financial reports, Saniona AB (SANION) has total liabilities worth Skr44.58 Million SEK (≈ $4.80 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SANION long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Saniona AB - Total Liabilities Trend (2012–2025)
This chart illustrates how Saniona AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SANION current and non-current assets.
Saniona AB Competitors by Total Liabilities
The table below lists competitors of Saniona AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Waterco Ltd
AU:WAT
|
Australia | AU$134.40 Million |
|
Silver X Mining Corp
V:AGX
|
Canada | CA$37.68 Million |
|
Theratechnologies Inc.
TO:TH
|
Canada | CA$79.19 Million |
|
Dexxos Participações S.A
SA:DEXP3
|
Brazil | R$568.91 Million |
|
PHA Co. Ltd
KQ:043370
|
Korea | ₩278.28 Billion |
|
Eastern Communications Co Ltd B
SHG:900941
|
China | $847.86 Million |
|
Mercuries Data Systems Ltd
TW:2427
|
Taiwan | NT$3.56 Billion |
|
Kolmar BNH Co. Ltd
KQ:200130
|
Korea | ₩294.21 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Saniona AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Saniona AB (SANION) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 13.03 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Saniona AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Saniona AB (2012–2025)
The table below shows the annual total liabilities of Saniona AB from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr44.58 Million ≈ $4.80 Million |
-58.69% |
| 2024-12-31 | Skr107.92 Million ≈ $11.61 Million |
+25.36% |
| 2023-12-31 | Skr86.08 Million ≈ $9.26 Million |
-14.76% |
| 2022-12-31 | Skr100.99 Million ≈ $10.87 Million |
-36.18% |
| 2021-12-31 | Skr158.25 Million ≈ $17.03 Million |
+78.36% |
| 2020-12-31 | Skr88.72 Million ≈ $9.55 Million |
+136.20% |
| 2019-12-31 | Skr37.56 Million ≈ $4.04 Million |
-13.88% |
| 2018-12-31 | Skr43.62 Million ≈ $4.69 Million |
+305.86% |
| 2017-12-31 | Skr10.75 Million ≈ $1.16 Million |
-34.93% |
| 2016-12-31 | Skr16.52 Million ≈ $1.78 Million |
+249.20% |
| 2015-12-31 | Skr4.73 Million ≈ $509.02K |
-29.19% |
| 2014-12-31 | Skr6.68 Million ≈ $718.87K |
-53.92% |
| 2013-12-31 | Skr14.50 Million ≈ $1.56 Million |
+51.63% |
| 2012-12-31 | Skr9.56 Million ≈ $1.03 Million |
-- |
About Saniona AB
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more